West Pharmaceutical Services, Inc. — Q1 2014 Form 10-Q Summary
Business Context and Reporting Period
West Pharmaceutical Services, Inc. designs and manufactures pharmaceutical packaging components, drug-delivery systems, safety and administration systems, and contract-manufacturing solutions. Reportable segments are Packaging Systems and Delivery Systems. The filing covers the unaudited three months ended March 31, 2014, compared with the three months ended March 31, 2013.
Financial Performance and Position
| Metric | Q1 2014 | Q1 2013 | Change |
|---|---|---|---|
| Net sales | $346.8 million | $339.4 million | +2.2% |
| Gross profit | $106.4 million | $111.7 million | -4.7% |
| Gross margin | 30.7% | 32.9% | -2.2 points |
| Operating profit | $39.3 million | $43.3 million | -9.2% |
| Operating margin | 11.3% | 12.8% | -1.5 points |
| Net income | $27.1 million | $31.7 million | -14.5% |
| Diluted EPS | $0.38 | $0.45 | -15.6% |
| Operating cash flow | $8.8 million | $18.9 million | -53.4% |
- Packaging Systems sales were $252.9 million, up 0.5%; operating profit fell to $51.4 million from $58.6 million. Sales excluding currency effects declined 0.4%.
- Delivery Systems sales were $94.0 million, up 6.6%; operating profit declined to a $0.2 million loss from $1.2 million of profit. Proprietary products represented 22.5% of segment sales versus 25.3% in the prior year.
- Capital expenditures were $31.7 million, down from $61.7 million. Investing cash outflow was $35.6 million, compared with $57.7 million.
- Cash and cash equivalents were $230.0 million at March 31, 2014, unchanged from year-end. Short-term investments were $11.7 million.
- Total debt was $404.9 million, up from $373.5 million at December 31, 2013. Net debt-to-total invested capital increased to 15.8% from 13.7%.
- Working capital was $459.0 million, up from $413.8 million, primarily reflecting higher accounts receivable and inventories and lower current liabilities.
- The company had $210.8 million of borrowing capacity under its revolving credit facility after outstanding borrowings and letters of credit. Management stated that the company was in compliance with all debt covenants.
Material Changes Versus the Prior Comparable Period
- Revenue growth was largely supported by favorable foreign currency effects and higher Delivery Systems contract-manufacturing sales. Excluding currency effects, consolidated sales increased 1.2%.
- Profitability weakened because of an unfavorable product mix, lower sales of high-value Packaging Systems products and Delivery Systems proprietary products, production inefficiencies, and higher wage, benefit, and other costs.
- Packaging Systems was affected by unusually strong first-quarter 2013 demand associated with customer inventory building, drug shortages, and new product launches.
- Research and development expense increased 9.9% to $10.0 million, including increased investment in next-generation packaging components.
- Consolidated SG&A declined 4.6% to $56.4 million, primarily because of lower corporate pension, stock-based compensation, incentive compensation, and intellectual-property costs.
- The effective tax rate increased to 27.6% from 22.0%, primarily because the 2013 period included a $1.3 million R&D tax-credit benefit and because of changes in geographic earnings mix.
- Operating cash flow declined due to lower net income, higher working-capital requirements, and increased income-tax payments.
Guidance, Outlook, Risks, and Unusual Items
- Management expected full-year 2014 net sales and operating profit to increase versus 2013, with longer-term improvement driven by demand for higher-quality products, capacity expansion, cost reduction, lean initiatives, emerging-market growth, and proprietary Delivery Systems products.
- The filing cautions that quarterly results are not necessarily indicative of full-year performance. Management planned continued capital investment in new products, expansion, emerging markets, and Delivery Systems proprietary products.
- A $20.0 million customer payment received in 2013 for exclusive SmartDose use was being recognized as development income over the agreement term. Unearned income was $18.6 million at March 31, 2014; the agreement contained no future minimum purchase commitment.
- SmartDose contingent consideration increased by $0.4 million to $4.7 million because of the time value of money and updated sales projections. Changes in projections, commercialization progress, probability of success, or discount rates could materially affect the liability.
- At March 31, 2014, the company had $2.7 million of net monetary assets denominated in Venezuelan bolivars, including $1.6 million of cash. A future change in the applicable exchange mechanism or significant devaluation could result in a pretax charge of up to the net monetary asset balance.
- Key risks include customer demand and inventory changes, product mix, competition, regulatory approval and commercialization of customer products, production and supply-chain interruptions, reliance on suppliers and partners, raw-material and labor costs, foreign-exchange movements, and healthcare legislation.
- The filing reported no material changes to previously disclosed legal proceedings, commitments, contingencies, market-risk exposures, or risk factors. Management stated that current legal matters were not expected to have a material adverse effect.
Important Facts for Investors to Verify
- Whether the expected full-year sales and operating-profit growth materialized despite the first-quarter margin decline.
- Recovery of Packaging Systems high-value product demand and improvement in product mix and production efficiency.
- Commercial progress, regulatory status, and customer adoption of SmartDose, CZ, safety systems, and other proprietary products.
- Trends in operating cash flow, accounts receivable, inventories, capital spending, and reliance on revolving-credit borrowings.
- Potential effects of foreign currency movements, particularly in Europe, Japan, and Venezuela.
- Future changes in the SmartDose contingent-consideration liability and recognition of the remaining customer payment.
- The company’s ability to maintain debt-covenant compliance and adequate liquidity while funding planned capital projects.